Candidate mechanisms for chemotherapy-induced cognitive changes
نویسندگان
چکیده
منابع مشابه
Potential mechanisms for chemotherapy-induced impairments in cognitive function.
PURPOSE/OBJECTIVES To review the domains of cognitive function and their corresponding neuroanatomic structures as well as present current evidence for neurotoxicity associated with specific chemotherapeutic agents and potential mechanisms for chemotherapy-induced cognitive impairments. DATA SOURCES Published research articles, review articles, and textbooks. DATA SYNTHESIS Chemotherapy doe...
متن کاملChemotherapy - induced cognitive impairments
Adjuvant chemotherapy has increased the survival of patients with numerous cancers with more than 60% of cancer patients surviving more than five years after diagnosis [1]. As improvements in cancer treatments lead to longer survival times for many cancers, researchers have moved towards investigating and improving quality of life for survivors. It is estimated that there are 22 million cancer ...
متن کاملChemotherapy-related changes in cognitive functioning
1359-6349/$ see front matter Copyright 2013 ECCO the European CanCer Organisation. All rights reserved. http://dx.doi.org/10.1016/j.ejcsup.2013.07.007 * Corresponding author. Address: Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Ple 121, 1066 CX, Amsterdam, The Netherlands. Tel.: +31 20 512 2328/2480. E-mail address: [email protected] (S.B. Schagen). Sann...
متن کاملMechanisms of chemotherapy-induced behavioral toxicities
While chemotherapeutic agents have yielded relative success in the treatment of cancer, patients are often plagued with unwanted and even debilitating side-effects from the treatment which can lead to dose reduction or even cessation of treatment. Common side effects (symptoms) of chemotherapy include (i) cognitive deficiencies such as problems with attention, memory and executive functioning; ...
متن کاملChemotherapy-induced nail changes: an unsightly nuisance.
P.S. is a 53-year-old female patient with stage IIB breast cancer. In November 2000, she received Adriamycin (Pfizer Inc., New York, NY) and Cytoxan (Bristol-Myers Squibb, New York, NY), along with Herceptin (Genentech, Inc., South San Francisco, CA), as part of a clinical trial. In July 2002, the patient was found to have a left supraclavicular axillary recurrence. Because of this recurrence, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Cancer
سال: 2007
ISSN: 1474-175X,1474-1768
DOI: 10.1038/nrc2073